

Myopathy caused by anoctamin 5 mutations and necrotizing vasculitis

Isabelle Pénisson-Besnier · Jean-Paul Saint-André ·
Debbie Hicks · Anna Sarkozy · Anne Croué ·
Judith Hudson · Hanns Lochmüller · Frédéric Dubas

Received: 30 December 2011 / Revised: 26 March 2012 / Accepted: 27 March 2012 / Published online: 19 April 2012
© Springer-Verlag 2012

Dear Sirs,

Recessive mutations in the *ANO5* gene, encoding anoctamin 5, cause either a proximal limb-girdle muscular dystrophy or a distal myopathy phenotype [2]. The latter has many similarities to Miyoshi myopathy, caused by mutations in the dysferlin gene. Both disorders usually manifest in young adults by initial calf muscle weakness, very high creatine kinase (CK) levels, and dystrophic features on muscle biopsy. Dysferlin immunostaining is normal in anoctaminopathy whereas it is absent in dysferlinopathy. This is the first report on muscle necrotizing vasculitis observed in a myopathy caused by *ANO5* gene mutations.

A 46-year-old man was admitted to a general hospital for malaise. He was diagnosed with *Chlamydia pneumoniae* infection and treated successfully with roxithromycin. A painless lower limb muscle weakness was also noticed. The first symptom was difficulty in running at age 34 years. Family history was negative for neuromuscular disease. Serum CK levels were 3,612 and 1,168 IU/l

(normal value <190). Left vastus lateralis biopsy, performed 2 weeks after admission, disclosed variation in fiber size and adipose infiltration. Many vessels were surrounded or infiltrated by inflammatory cells (numerous T lymphocytes CD3+CD8– and a few histiocytes CD68+). The wall of several arterioles exhibited fibrinoid necrosis and nuclear debris, and some vessels were occluded (Fig. 1a–c). On the basis of these pathological findings, the patient was given corticosteroids at 1 mg/kg/day.

When referred to our center 2 months later, he was in a good general condition and denied improvement of muscle strength. His gait was slightly waddling, and walking on tip-toes was impossible. All the thigh and posterior leg muscles were wasted in accordance with muscle imaging (Fig. 2a–c). Manually tested muscle strength (MRC scale) was 3–/5 for foot and knee extensors, 3/5 for knee flexors, around 4/5 for pelvic muscles, and 5/5 for upper limb muscles. The rest of the muscular and general examination was normal. CK level was 1,951 IU/l. The following investigations were normal or negative: chest X-ray, respiratory function tests, electrocardiogram, echocardiography, erythrocyte sedimentation rate, C-reactive protein, eosinophil count, search for proteinuria and microscopic hematuria, hepatitis and HIV blood tests, serum protein electrophoresis, antinuclear and anti-neutrophil cytoplasmic antibodies (performed on two blood samples including one retrieved before corticosteroids introduction). A genetically determined muscular dystrophy was suspected and corticosteroids were stopped within 2 months. A second left vastus lateralis biopsy showed several necrotic or regenerative fibers, increased endomysial connective tissue and fat infiltration. No inflammatory lesions were present. Dystrophin, dystroglycans, sarcoglycans, caveolin, dysferlin and telethonin immunostaining were normal. Calpain3 was found to be reduced

I. Pénisson-Besnier (✉) · F. Dubas
Département de Neurologie, Centre de référence Maladies Neuromusculaires, Centre Hospitalier et Universitaire d'Angers, 4, rue Larrey, 49933 Angers Cedex 9, France
e-mail: ispenisson-besnier@chu-angers.fr

J.-P. Saint-André · A. Croué
Département de Pathologie Cellulaire et Tissulaire, Centre Hospitalier Universitaire d'Angers, Angers, France

D. Hicks · A. Sarkozy · J. Hudson · H. Lochmüller
Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK




Fig. 1 Paraffin embedded sections of the first quadriceps muscle biopsy. Hematoxylin–eosin–safran staining. **a** A small vessel is surrounded and invaded by an extensive inflammatory infiltrate, **b**, **c** serial sections of an arteriole showing recent thrombosis and necrosis


of the media which is vacuolated and contains pycnotic nuclei. **d** Congo red stained section showing congophilic deposits within the wall of an arteriole

by Western blot analysis but no mutation was detected in the *CAPN3* gene. Weakness remained confined to lower limb muscles at age 56 and neither thrombosis nor other systemic features occurred during follow-up. Diagnosis of Miyoshi-like myopathy with normal dysferlin expression was made by default until direct sequence analysis of *ANO5* identified two novel heterozygous mutations: exon 19 variant c. 2235+1G>A predicted to be pathogenic as it disrupts the consensus splice site and exon 7 variant c. 400C>T which results in the substitution of a conserved basic histidine residue with a neutral polar tyrosine residue (p. His134Tyr) and is predicted as pathogenic by in silico analysis. No mutation was detected in the two unaffected siblings and the mother was identified heterozygous for c. 400C>T. Father's DNA was unavailable. Congo red staining, performed after *ANO5* gene analysis, disclosed congophilic deposits, birefringent under polarized light, within the wall of several arterioles in both biopsies (Fig. 1d).

This is the first case showing that anoctaminopathy may cause a secondary reduction in calpain3 muscle expression. It also confirms that amyloid deposits are present in muscle blood vessel walls [12]. Both features are similar

to that reported in primary dysferlinopathies [1, 14]. Two hypotheses may explain the necrotizing vasculitis of muscle which has not been observed in anoctaminopathy previously. (1) Unrelated to the muscular dystrophy, the preceding *Chlamydia pneumoniae* infection may have caused vasculitis; cutaneous vasculitis was reported in context similar case [16]. (2) The vasculitis may be related to anoctaminopathy, as similar inflammatory features are observed in other muscular dystrophies, especially dysferlinopathy, and often lead to misdiagnosis [3, 6, 11, 13, 15]. In dysferlinopathy, the infiltrates are endomysial or perivascular, and consist of T-cells and macrophages. Among the few muscle histology reports in anoctaminopathies [2, 4, 7, 9, 10, 12], inflammatory infiltrates were noticed in a single patient but their location was not reported [7]. The mutations found in our patient affect the cytoplasmic topological domain and the 7th transmembrane domain of the anoctamin 5 protein. Its precise function is not known [5]. Two studies suggested it may play a role in the muscle membrane repair pathway [2, 8]. In conclusion, muscle vasculitis could be a feature of anoctaminopathies, and *ANO5* gene analysis is warranted if compatible phenotype.

Fig. 2 **a, b** Frontal and posterior views of the patient's lower limbs showing severe atrophy of vasti, hamstrings and posterior leg muscles. **c** Muscle CT scan at (**c1**) pelvis, (**c2**) thigh, and (**c3**) leg levels showing symmetric fatty infiltration of vasti, hamstrings, and mostly gastrocnemius (*Ga*) muscles while rectus femoris (*RF*), sartorius (*S*), gracilis (*Gr*) and the anterior leg muscles are spared



Conflicts of interest None.

References

1. Anderson LV, Harrison RM, Pogue R et al (2000) Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). *Neuromuscul Disord* 10:553–559
2. Bolduc V, Marlow G, Boycott KM et al (2010) Recessive mutations in the putative calcium-activated chloride channel anoctamine 5 cause proximal LGMDL and distal MMD3 muscular dystrophies. *Am J Hum Genet* 86:213–221
3. Confalonieri P, Oliva L, Andreetta F et al (2003) Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. *J Neuroimmunol* 142:130–136
4. Deschauer M, Joshi PR, Gläser D, Hanisch F, Stoltenburg G, Zierz S (2011) Muscular dystrophy due to mutations in anoctamin 5: clinical and molecular genetic findings. *Nervenarzt* 82:1596–1603
5. Duran C, Hartzell HC (2011) Physiological roles and diseases of Tmem16/anoctamin proteins: are they all chloride channels? *Acta Pharmacol Sin* 32:685–692
6. Gallardo E, Rojas-García R, de Luna N, Pou A, Brown RH Jr, Illa I (2001) Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. *Neurology* 57:2136–2138
7. Hicks D, Sarkozy A, Muelas N et al (2011) A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. *Brain* 134:171–182
8. Jaiswal JK, Marlow G, Summerill G et al (2007) Patients with a non-dysferlin Miyoshi myopathy have a novel membrane repair defect. *Traffic* 8:77–88
9. Jarry J, Rioux MF, Bolduc V, Robitaille Y, Khoury V, Thiffault I, Tétreault M, Loisel L, Bouchard JP, Brais B (2007) A novel autosomal recessive limb-girdle muscular dystrophy with quadriceps atrophy maps to 11p13-p12. *Brain* 130:368–380
10. Mahjneh I, Jaiswal J, Lamminen A, Somer M, Marlow G, Kiuru-Enari S, Bashir R (2010) A new distal myopathy with mutation in anoctamin 5. *Neuromuscul Disord* 20:791–795
11. Mc Nally EM, Ly CT, Rosenmann H et al (2000) Splicing mutations in dysferlin produces limb-girdle muscular dystrophy with inflammation. *Am J Med Genet* 91:305–312
12. Milone M, Liewluk T, Winder TL, Pianosi PT (2012) Amyloidosis and exercise intolerance in ANO5 muscular dystrophy. *Neuromuscul Disord* 22:13–15
13. Nguyen K, Bassez G, Krahn M et al (2007) Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. *Arch Neurol* 64:1176–1182
14. Rosales XQ, Gastier-Foster JM, Lewis S et al (2010) Novel diagnostic features of dysferlinopathies. *Muscle Nerve* 42:14–21
15. Rowin J, Meriggioli MN, Cochran EJ, Sanders DB (1999) Prominent inflammatory changes on muscle biopsy in patients with Miyoshi myopathy. *Neuromuscul Disord* 9:417–420
16. Sakuma H, Niiyama S, Amoh Y, Katsuoka K (2011) *Chlamydomydia pneumoniae* infection induced nodular vasculitis. *Case Rep Dermatol* 3:263–267